Erik Domingues, MD: Long-Term Vitiligo Management and Repigmentation

August 24, 2026

Dr. Domingues discusses his tips for managing vitiligo as a chronic autoimmune disease, emphasizing patient engagement and setting realistic expectations for repigmentation. He reviews differences between nonsegmental and segmental vitiligo, the value of serial photography for monitoring perifollicular and marginal repigmentation, and how treatment response can vary by anatomic site and hair follicle density. Dr. Domingues also reviews topical ruxolitinib for nonsegmental vitiligo, emphasizing repigmentation develops progressively over time and that continued treatment and follow-up is critical for maintaining meaningful improvement.

Topics Covered:

Distinguishing nonsegmental and segmental vitiligo in clinical practice
Monitoring repigmentation and setting realistic treatment expectations
Long-term management with topical therapy and emerging combination approaches

MORE EXPERT PERSPECTIVES IN VITILIGO

Iltefat Hamzavi, MD: The Role of JAK Inhibition in Treating Vitiligo

Iltefat Hamzavi, MD, discusses the evolving role of Janus kinase (JAK) inhibition in the treatment of vitiligo. He compares JAK inhibitors such as topical ruxolitinib

Alexa Hetzel, PA-C: Improving Vitiligo Facial Repigmentation with Topical JAK Inhibitors

Alexa Hetzel, PA-C, discusses the clinical efficacy of a non-steroidal topical JAK inhibitor that helps patients with vitiligo achieve significant facial repigmentation over 52 weeks.

Tristan Hasbargen, PA-C: Setting Expectations for a Long-Term Approach to Repigmentation

Tristan Hasbargen, PA-C, of Dermatology Associates of Tallahassee, discusses the treatment of Vitiligo, with a focus on helping patients develop realistic expectations for the repigmentation

David Rosmarin, MD: Efficacy of Ruxolitinib Cream in Progressive and Stable Vitiligo

David Rosmarin, MD, the chair of the Department of Dermatology at Indiana University in Indianapolis, discusses results from a pooled subgroup analysis of the 104-week

Seemal Desai, MD, FAAD: Providing Effective Treatment for Patients with Facial Vitiligo

Dr. Desai discusses treatment strategies for patients with Vitiligo, focusing specifically on the use of Ruxolitinib> cream 1.5% for depigmented areas affecting the face and

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Treating Patients with Vitiligo on the Hands

Chantel Hillestad discusses the unique challenges involved in treating Vitiligo affecting the hands, an area that is often more resistant to repigmentation due to lower

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Restoring Pigmentation in Patients with Vitiligo

Chantel Hillestad, RN, MSN, DCNP, FNP-C, shares clinical experience using ruxolitinib to restore pigmentation in vitiligo patients across all age groups. Topics Covered: Ruxolitinib for

Seemal Desai, MD, FAAD: Assessing Efficacy of Ruxolitinib in Characteristic Subgroups for Patients with Vitiligo

Dr. Desai reviews findings from a post-hoc analysis of the TRuE-V1 and TRuE-V2 clinical trials, focusing on the efficacy and durability of treatment with Ruxolitinib>

Jennifer Silva, APRN-DNP: Safety Considerations for Treating Patients with Vitiligo

Jennifer Silva discusses important safety considerations when treating patients with Vitiligo using JAK inhibitors, emphasizing the need for clear patient counseling regarding black box warnings

Julien Seneschal, MD, PhD: An Update on Topical and Systemic JAK Inhibition for Vitiligo

Dr. Seneschal provides an update on the evolving role of JAK inhibitors in the treatment of Vitiligo, reviewing both currently available topical therapies and investigational

Jennifer Silva, APRN-DNP: Providing Adequate Treatment for Patients with Vitiligo

Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies. Topics Covered: Challenges in vitiligo treatment Strategies

Iltefat Hamzavi, MD: Combining Phototherapy with Topical Therapy in Patients with Vitiligo

Dr. Hamzavi and James Del Rosso, DO, Editor-in-Chief of Journal of Clinical and Aesthetic Dermatology, discuss practical treatment considerations for patients with Vitiligo using Ruxolitinib>

David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

Dr. Rosmarin reviews key updates in the treatment of Vitiligo, expanding on topics presented during his session at the Masterclasses in Dermatology Meeting. His discussion

Gina Mangin, MPAS, PA-C: Coaching Pearls for Patients with Vitiligo

Gina Mangin discusses patient-centered strategies for managing Vitiligo, emphasizing the importance of encouragement, education, and ongoing motivation throughout the treatment journey. Her presentation highlights how

Gina Mangin, MPAS, PA-C: Using Light Box Therapy for Patients with Vitiligo

Gina Mangin, MPAS, PA-C, discusses the role of light box therapy in vitiligo management, with a focus on setting clear expectations around treatment timelines and

Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo

Nada Elbuluk, MD, discusses the importance of assessing psychological comorbidities in patients with vitiligo by gathering key social information, including daily activities, living situation, and

Shanna Miranti, MPAS, PA-C: Prescribing Ruxolitinib for Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses prescribing considerations for topical ruxolitinib in patients with vitiligo, emphasizing the importance of prior treatment attempts with topical corticosteroids and

James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster

Shanna Miranti, MPAS, PA-C: Assessing Treatment Efficacy in Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years.

Shanna Miranti, MPAS, PA-C: Managing the Psychosocial Impact of Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the bimodal distribution of vitiligo in male and female individuals and the necessary counseling for those who are managing their

Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources

Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially

JCAD Archives